Related Tags >> Astellas Pharma Tarceva Genentech Macugen

OSI Pharmaceuticals News

Most Popular OSI Pharmaceuticals Story

Pfizer gets new cancer team to advance key drugs

May 15, 2008 — 5:59am ET

With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...

OSI Pharmaceuticals Press Releases

Array BioPharma Names Karsten Witt, M.D., Vice President of Clinical Sciences
Verastem Appoints Jonathan Pachter as Head of Research
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.
Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty P
Kenneth Lee Appointed to BioCryst Pharmaceuticals’ Board of Directors

Latest Headlines

Astellas buys OSI for $4B
May 17, 2010
OSI shares rise as bid deadline nears
May 14, 2010
Astellas tries board coup in hostile bid for OSI
March 17, 2010
Out to ignite a bidding war, OSI rejects Astellas' bid
March 16, 2010
OSI shares soar as Astellas brawls over rejected bid
March 2, 2010
Astellas makes $3.5B hostile bid for OSI
March 1, 2010
Aveo grabs $20M in expanded OSI collaboration
July 21, 2009
OSI Pharma to consolidate U.S. workers
July 8, 2009
Tarceva successful as maintenance therapy
November 7, 2008
Pfizer gets new cancer team to advance key drugs
May 15, 2008
ALSO NOTED: Genta inks licensing deal on oncology program; Abbott, et al, target Tarceva gene test; Gilead submits marketing ap
March 7, 2008
ALSO NOTED: Immunogen licenses antibody; GenVec amends trial plans; analyst bullish on biotech; and much more...
January 3, 2008
OSI, AVEO sign small molecules pact
October 2, 2007
Press Release: Enzon Receives FDA Clearance of HIF-1 alpha Investigational New Drug Application
January 26, 2007
OSI looks to unload Macugen, exit eye diseases
November 6, 2006
European committee gives negative ruling on Tarceva
July 27, 2006
ALSO NOTED: BioMarin gets Orapred approval; FDA rejects Organon app; and much more...
June 1, 2006
ALSO NOTED: Celera moves to cut staff; FDA expands Emend use; FDA approves Perrigo gel; and much more...
January 10, 2006
ALSO NOTED: FDA panel recommends Zostavax; Serono pleads guilty; Wistar Institute sells royalties;and much more...
December 15, 2005
OSI delays $935M Eyetech deal
November 10, 2005

Paid Research Reports

More Research Reports >>